Therapies with FGFR and phosphoinositide 3-kinases (PI3K) inhibitors have been used for other cancers with FGFR3 and PIK3CA mutations, and so we tested the HPV+ UM-SCC-47 and UPCI-SCC-154, and the HPV- UT-SCC-60A cell lines for sensitivity to FGFR inhibitor AZD4547, and PI3K inhibitors BEZ235 and BKM120 (33–35). This evidence concerns the gene PIK3CA and cancer.